The economics of adalimumab for ulcerative colitis.

about

Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review.Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.

P2860

Q33871726-484CCF5A-6EA5-41A1-A731-13FD0C08C398 Q37322514-D042AA96-067A-4AE1-B912-52C7B208DDC8

P2860

The economics of adalimumab for ulcerative colitis.

Item

http://www.wikidata.org/entity/Q39024280

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The economics of adalimumab for ulcerative colitis.

@en

The economics of adalimumab for ulcerative colitis.

@nl

type

Item

label

The economics of adalimumab for ulcerative colitis.

@en

The economics of adalimumab for ulcerative colitis.

@nl

prefLabel

The economics of adalimumab for ulcerative colitis.

@en

The economics of adalimumab for ulcerative colitis.

@nl

P1476

The economics of adalimumab for ulcerative colitis.

@en

P2093

Feng Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab for induction and maintenance therapy for ulcerative colitis

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.

Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

P304

373-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2015.1031113

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25817776

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

The economics of adalimumab for ulcerative colitis.

about

P2860

P2860

The economics of adalimumab for ulcerative colitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921